Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 83, Issue 16, 1991, Pages 1164-1168

  Negoro, Shunichi ^a   Fukuoka, Masahiro ^a   Masuda, Noriyuki ^a   Takada, Minoru ^a   Kusunoki, Yoko ^a   Matsui, Kaoru ^a   Takifuji, Nobuhide ^a   Kudoh, Shinzoh ^a   Niitani, Hisanobu ^b   Taguchi, Tetsuo ^c  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LUNG CANCER; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TOXICITY;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EVALUATION; FEMALE; HEMATOLOGIC DISEASES; HUMAN; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0025851286     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/83.16.1164     Document Type: Article

References (24)

1. Wall ME, Wani MC, Cook CE, et al: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptothcca acuminata. J Am Chem Soc 88:3888–3890, 1966
2. Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878, 1985
3. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565–5569, 1987
4. Li LH, Fraser TJ, Oun EJ, et al: Action of camptothecin on mammalian cells in culture. Cancer Res 32:2643–2650, 1972
5. Drewinko B, Freireich EJ, Gottlieb JA: Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34:747–750, 1974
6. Gallo RC, Whang-Peno J, Adamson RH: Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46:789–795, 1971
7. Gottueb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461–470, 1970
8. Muogia FM, Creaven PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56:515–521, 1972
9. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Phase n study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95–101, 1972
10. Gottueb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103–105, 1972
11. Creaven PJ, Allen LM, Muggia FM: Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: Relation to dose and toxicity. Cancer Chemother Rep 56:573–578, 1972
12. Yang J, Han J, Xu B: Distribution and excretion of 10-hydroxycamptothecin and its influence on immune response. Acta Pharmacol Sin 1:44–48, 1980
13. Creasey WA, Richards M, Gil D, et al: Action of (S)-10-hydroxycamptothecin on P388 leukemia and distribution of the drug in mice. Cancer Treat Rep 67:179–182, 1983
14. Nagata H, Kaneda N, Furuta T, et al: Action of 7-ethylcamptothecin on tumor cells and its disposition in mice. Cancer Treat Rep 71:341–348, 1987
15. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumors. J Pharmacobiodyn 10:148–151, 1987
16. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(l-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944–5947, 1987
17. Matsuzaki T, Yokokura T, Mutai M, et al: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308–312, 1988
18. Taguchi T, Wakui A, Hasegawa K, et al: Phase I clinical study of CPT-11. Research group of CPT-11. Gan To Kagaku Ryoho 17:115–120, 1990
19. Ohno R, Okada K, Masaoka T, et al An early phase n study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907–1912, 1990
20. Nagata H: Flow cytometric analysis of the effect of an antitumor alkaloid, camptothecin on cell cycle progression of KB cell. J Aichi Med Univ Assoc 15:683–699, 1987
21. Furuta T, Yokokura T: Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Gan To Kagaku Ryoho 17:121-130, 1990
22. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207–214, 1981
23. Kaneda N, Nagata H, Furuta T, et al: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715–1720, 1990
24. Kaneda N, Yokokura T: Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721–1725, 1990